Minocycline augmentation in older adults with persistent depression: an open label proof of concept study.

TitleMinocycline augmentation in older adults with persistent depression: an open label proof of concept study.
Publication TypeJournal Article
Year of Publication2020
AuthorsAvari JN, Kanellopoulos D, Solomonov N, Oberlin L, Alexopoulos GS
JournalInt Psychogeriatr
Volume32
Issue7
Pagination881-884
Date Published2020 07
ISSN1741-203X
KeywordsAged, Aged, 80 and over, Depression, Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant, Drug Synergism, Humans, Male, Middle Aged, Minocycline, Proof of Concept Study, Treatment Outcome
Abstract

Less than 40% of depressed older adults treated with an antidepressant achieve remission. Incomplete response to treatment is common. Current augmentation strategies have limited efficacy, and many have side effects that restrict their utilization in older adults. We conducted the first open pilot trial of minocycline augmentation in older adults who had failed to achieve remission after adequate psychopharmacologic treatment. Subjects older than 55 years of age with major depression and failure to achieve substantial improvement of depressive symptoms after at least 6 weeks of antidepressant treatment were given augmentation with minocycline 100 mg twice daily over an 8-week period. At the end of 8 weeks of augmentation with minocycline, 31% (4/13) patients achieved remission. Remitters had higher baseline ratings of hopelessness and apathy. Minocycline was well tolerated with no reported adverse events or discontinuation due to intolerance. Larger placebo-controlled studies are needed to evaluate the effects of minocycline augmentation in older adults who had failed to achieve remission after adequate treatment with antidepressants.

DOI10.1017/S1041610220001313
Alternate JournalInt Psychogeriatr
PubMed ID32690123
Grant ListP50 MH113838 / MH / NIMH NIH HHS / United States
T32 MH019132 / MH / NIMH NIH HHS / United States